WO2007059323A2 - Entites chimiques, compositions et methodes - Google Patents

Entites chimiques, compositions et methodes Download PDF

Info

Publication number
WO2007059323A2
WO2007059323A2 PCT/US2006/044753 US2006044753W WO2007059323A2 WO 2007059323 A2 WO2007059323 A2 WO 2007059323A2 US 2006044753 W US2006044753 W US 2006044753W WO 2007059323 A2 WO2007059323 A2 WO 2007059323A2
Authority
WO
WIPO (PCT)
Prior art keywords
trans
piperidyl
fluoro
methylphenyl
hydroxyphenyl
Prior art date
Application number
PCT/US2006/044753
Other languages
English (en)
Other versions
WO2007059323A3 (fr
Inventor
Scott Collibee
Zhe Yang
Luke Ashcraft
Gustave Bergnes
Bradley P. Morgan
David J. Morgans, Jr.
Original Assignee
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Inc. filed Critical Cytokinetics, Inc.
Priority to EP06837964A priority Critical patent/EP1962846A2/fr
Publication of WO2007059323A2 publication Critical patent/WO2007059323A2/fr
Publication of WO2007059323A3 publication Critical patent/WO2007059323A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Ri is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
  • R 2 is chosen from optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, hydroxy, and optionally substituted amino;
  • R 3 is chosen from hydrogen and optionally substituted alkyl
  • R 4 is chosen from hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted heteroaryl, aminocarbonyl, sulfonyl, optionally substituted alkoxycarbonyl, and optionally substituted cycloalkyl;
  • Rg is chosen from hydrogen and optionally substituted alkyl
  • R 6 is chosen from optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, hydroxy, and optionally substituted amino provided that: the compound of Formula I is not dimethyl l-benzylpiperidine-3,5-dicarboxylate; methyl 5-acetyl-l-benzylpiperidine-3-carboxylate; dimethyl l-benzyl-4-phenylpiperidine-3,5- dicarboxylate; ( 1 -methyl-4-phenylpiperidine-3 ,5-diyl)bis(phenylmethanone) ; ( 1 -benzyl- 4-phenylpiperidine-3,5-diyl)bis(phenylmethanone); (l-(2-hydroxyethyl)-4- phenylpiperidine ⁇ 3,5-diyl)bis(phenylmethanone); (
  • composition comprising a therapeutically effective amount of at least one chemical entity described herein together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients.
  • a packaged pharmaceutical composition comprising a pharmaceutical composition described herein; and instructions for using the composition to treat a patient suffering from a cellular proliferative disease.
  • a method for treating a patient having a cellular proliferative disease comprising administering to the patient an effective amount of at least one chemical entity described herein.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • -CONH2 is attached through the carbon atom.
  • optionally or “optionally” is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • optionally substituted alkyl encompasses both “alkyl” and “substituted alkyl” as defined below.
  • Alkyl encompasses straight chain and branched chain having the indicated number of carbon atoms, usually from 1 to 20 carbon atoms, for example 1 to 8 carbon atoms, such as 1 to 6 carbon atoms.
  • C 1 -Ce alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon atoms.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3- hexyl, 3-methylpentyl, and the like.
  • Alkylene is another subset of alkyl, referring to the same residues as alkyl, but having two points of attachment. Alkylene groups will usually have from 2 to 20 carbon atoms, for example 2 to 8 carbon atoms, such as from 2 to 6 carbon atoms.
  • Co alkylene indicates a covalent bond and Ci alkylene is a methylene group.
  • alkyl residue having a specific number of carbons is named, all branched and straight chain versions having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl and isopropyl.
  • “Lower alkyl” refers to alkyl groups having one to four carbons.
  • Alkenyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene.
  • the group may be in either the cis or trans configuration about the double bond(s).
  • Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), ⁇ ro ⁇ -2-en-2-yl, cycloprop-1-en-l-yl; cycloprop-2-en-l-yl; butenyls such as but-1-en-l-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien-2-yl, cyclobut-1-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien-l-yl; and the like.
  • Alkynyl refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.
  • Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-l-yl, prop-2-yn-l-yl; butynyls such as but-1-yn-l-yl, but-l-yn-3-yl, but-3-yn-l-yl; and the like.
  • an alkynyl group has from 2 to 20 carbon atoms and in other embodiments, from 3 to 6 carbon atoms.
  • Cycloalkyl indicates a non-aromatic carbocyclic ring, usually having from 3 to
  • ring carbon atoms 7 ring carbon atoms.
  • the ring may be saturated or have one or more carbon-carbon double bonds.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cyclohexenyl, as well as bridged and caged saturated ring groups such as norbornane.
  • alkoxy is meant an alkyl group of the indicated number of carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentyloxy, and the like.
  • Alkoxy groups will usually have from 1 to 7 carbon atoms attached through the oxygen bridge.
  • “Lower alkoxy” refers to alkoxy groups having one to four carbons.
  • acyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms.
  • a C-C ⁇ alkoxycarbonyl group is an alkoxy group having from 1 to 6 carbon atoms attached through its oxygen to a carbonyl linker.
  • amino is meant the group -NH 2 .
  • “Mono- and di-(alkyl)amino” encompasses secondary and tertiary alkyl amino groups, wherein the alkyl groups are as defined above and have the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino. [0021] The term "aminocarbonyl” refers to the group -CONR ⁇ , where
  • R b is chosen from H, optionally substituted C-C ⁇ alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R c is independently chosen from hydrogen and optionally substituted Ci-C 4 alkyl; or R and R c taken together with the nitrogen to which they are bound, form an optionally substituted 5- to 7-membered nitrogen-containing heterocycloalkyl which optionally includes 1 or 2 additional heteroatoms selected from O, N, and S in the heterocycloalkyl ring; where each substituted group is independently substituted with one or more substituents independently selected from Cj-C 4 alkyl, aryl, heteroaryl, aryl-Cj-C 4 alkyl-, heteroaryl-Q-C- ⁇ alkyl-, Ci-C 4 haloalkyl, -OCi-C 4 alkyl, -OCi-C 4 alkylphenyl, - Ci-C 4 alkyl-OH, -OC,-C 4 haloalkyl, halo, -OH, -NH 2 , -Ci-C 4 alkyl-NH 2 , -N(Ci-C 4
  • 6-membered carbocyclic aromatic rings for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and tetralin; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
  • aryl includes 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocycloalkyl ring containing 1 or more heteroatoms chosen from N, O, and S.
  • bicyclic ring systems wherein only one of the rings is a carbocyclic aromatic ring, the point of attachment may be at the carbocyclic aromatic ring or the heterocycloalkyl ring.
  • Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
  • Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding "-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
  • Aryl does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings is fused with a heterocycloalkyl aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein.
  • aryloxy refers to the group -O-aryl.
  • RS is not hydrogen and wherein substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from: -R a , -OR b , optionally substituted amino (including -NR c COR b , -NR C CO 2 R ⁇ -NR 0 CONR 13 R 0 , -NR 13 C(NR ⁇ NR 13 R 0 , -NR 11 C(NCN)NR 13 R 0 , and -NR 0 SO 2 R 3 ), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR b
  • Rb is chosen from H, optionally substituted Ci-C 0 " alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R c is independently chosen from hydrogen and optionally substituted Ci-C 4 alkyl; or
  • Rb and R c and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from Ci-C 4 alkyl, aryl, heteroaryl, 8TyI-C 1 -C 4 alkyl-, heteroaryl-Ci-C 4 alkyl-, Ci-C 4 haloalkyl,
  • -OC1-C4 alkyl -OC1-C4 alkyl, -OC1-C4 alkylphenyl, -C1-C4 alkyl-OH, -OC1-C4 haloalkyl, halo, -OH, -NH2, -C1-C4 alkyl-NH2, -N(Ci-C 4 alkyl)(Ci-C4 alkyl), -NH(Ci-C4 alkyl), -N(Ci-C 4 3UCyI)(C 1 -C 4 alkylphenyl), -NH(C 1 -C 4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, or heteroaryl), -CO2H, -C(O)OC 1-C4 alkyl, -CON(Ci-C 4 alkyl)(C 1 -C 4 alkyl), -CON
  • Haloalkyl indicates alkyl as defined above having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms.
  • haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
  • Heteroaryl encompasses:
  • heteroatoms chosen from N, O, and
  • bicyclic heterocycloalkyl rings containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms chosen from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and tricyclic heterocycloalkyl rings containing one or more, for example, from 1 to 5, or in certain embodiments, from 1 to 4, heteroatoms chosen from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring.
  • heteroaryl includes a 5- to 7-membered heterocycloalkyl, aromatic ring fused to a 5- to 7-membered cycloalkyl or heterocycloalkyl ring.
  • bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment may be at either ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another.
  • the total number of S and O atoms in the heteroaryl group is not more than 2.
  • the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4-pyrazinyl, 2,4-pyrimidinyl, 3,5- pyrimidinyl, 2,3-pyrazolinyl, 2,4-imidazolinyl, isoxazolinyl, oxazolinyl, thiazolinyl, thiadiazolinyl, tetrazolyl, thienyl, benzothiophenyl, furanyl, benzofuranyl, benzoimidazolinyl, indolinyl, pyridazinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8-tetrahydroisoquinolinyl.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding "- idene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • Heteroaryl does not encompass or overlap with aryl, cycloalkyl, or heterocycloalkyl, as defined herein [0029]
  • Substituted heteroaryl also includes ring systems substituted with one or more oxide (-O " ) substituents, such as pyridinyl N-oxides.
  • heterocycloalkyl is meant a single, non-aromatic ring, usually with 3 to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms.
  • the ring may be saturated or have one or more carbon-carbon double bonds.
  • Suitable heterocycloalkyl groups include, for example (as numbered from the linkage position assigned priority 1), 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 2-piperidyl, 3- piperidyl, 4-piperidyl, and 2,5-piperizinyl.
  • Morpholinyl groups are also contemplated, including 2-morpholinyl and 3 -morpholinyl (numbered wherein the oxygen is assigned priority 1).
  • Heterocycloalkyl also includes bicyclic ring systems wherein one non-aromatic ring, usually with 3 to 7 ring atoms, contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms; and the other ring, usually with 3 to 7 ring atoms, optionally contains 1-3 heteratoms independently selected from oxygen, sulfur, and nitrogen and is not aromatic.
  • modulation refers to a change in activity as a direct or indirect response to the presence of compounds of Formula I relative to the activity in the absence of compounds of Formula I.
  • the change may be an increase in activity or a decrease in activity, and may be due to the direct interaction of the compound with the kinesin, or due to the interaction of the compound with one or more other factors that in turn affect kinesin activity.
  • the presence of the compound may, for example, increase or decrease kinesin activity by directly binding to the kinesin, by causing (directly or indirectly) another factor to increase or decrease the kinesin activity, or by (directly or indirectly) increasing or decreasing the amount of kinesin present in the cell or organism.
  • sulfanyl includes the groups: -S-(optionally substituted (Ci-C 6 )alkyl),
  • sulfanyl includes the group Ci-C ⁇ alkylsulfanyl.
  • sulfinyl includes the groups: -S(O)-(optionally substituted (Ci-
  • sulfonyl includes the groups: -S( ⁇ 2 )-(optionally substituted (C 1 -
  • substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from:
  • -R ⁇ -OR b optionally substituted amino (including -NR c COR b , -NR 0 CO 2 R 3 , -NR 0 CONR 15 R 0 , -NR b C(NR°)NR b R c , -NR 11 C(NCN)NR 11 R 0 , and -NR 0 SO 2 R 3 ), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR b ), optionally substituted alkoxycarbonyl (such as -C ⁇ 2R b ), aminocarbonyl (such as -CONR 6 R 0 ), -OCOR b , -OCO 2 R 3 , -OCONRV, sulfanyl (such as SR b ), sulfinyl (such as -SOR a
  • R c is independently chosen from hydrogen and optionally substituted C 1 -C4 alkyl; or
  • R b and R c and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from Ci-C 4 alkyl, aryl, heteroaryl, 3TyI-Ci-C 4 alkyl-, heteroaryl-Q-Q.
  • substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl refer respectively to alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from:
  • -R a , -OR b optionally substituted amino (including -NR c COR b , -NR 0 CO 2 R 3 , -NR c CONR b R c , -NR b C(NR c )NR b R c , -NR ⁇ (NCN)NR 6 R 0 , and -NR 0 SO 2 R 3 ), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR b ), optionally substituted alkoxycarbonyl (such as -C0 2 R b ), aminocarbonyl (such as -CONR 13 R 0 ), -OCOR b , -OCO 2 R a , -OCONR 15 R 0 , sulfanyl (such as SR b ), sulfiny
  • R b is chosen from H, optionally substituted Ci -Ce alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • R° is independently chosen from hydrogen and optionally substituted C 1 -C 4 alkyl
  • R b andR c and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from Ci -C 4 alkyl, aryl, heteroaryl, aryl-Ci -C 4 alkyl-, heteroaryl-Ci -C 4 alkyl-, Ci-C 4 haloalkyl, -OCi-C 4 alkyl, -OCi-C 4 alkylphenyl, -Ci-C 4 alky 1-OH, -OCi-C 4 haloalkyl, halo, -OH, -NH 2 , -C 1 -C 4 alkyl-NH 2 , -N(Ci-C 4 alkyl)(C r C 4 alkyl), -NH(Cj-C 4 alkyl),
  • -C(O)Ci-C 4 alkyl -C(O)Ci-C 4 alkylphenyl, -C(O)Ci-C 4 haloalkyl, -OC(O)C 1 -C 4 alkyl, - SO 2 (Ci-C 4 alkyl), -SO 2 (phenyl), -SO 2 (C]-C 4 haloalkyl), -SO 2 NH 2 , -SO 2 NH(Ci-C 4 alkyl), -SO 2 NH(phenyl), -NHSO 2 (C]-C 4 alkyl), -NHSO 2 (phenyl), and -NHSO 2 (Ci-C 4 haloalkyl).
  • substituted alkoxy refers to alkoxy wherein the alkyl constituent is substituted (i.e., -O-(substituted alkyl)) wherein “substituted alkyl” refers to alkyl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from:
  • -R a , -OR b optionally substituted amino (including -NR c COR b , -NR 0 CO 2 R 3 , -NR 0 CONRV, -NR b C(NR c )NR b R c , -NR 13 C(NCN)NR 13 R 0 , and -NR c SO 2 R a ), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR b ), optionally substituted alkoxycarbonyl (such as -CO 2 R b ), aminocarbonyl (such as -CONR b R c ), -OCOR b , -OCO 2 R 3 , -OCONRV, sulfanyl (such as SR b ), sulfinyl (such as -SOR
  • R b is chosen from H, optionally substituted Ci-Ce alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • R c is independently chosen from hydrogen and optionally substituted Ci-C 4 alkyl; or
  • R b andR c and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C 1 -C4 alkyl, aryl, heteroaryl, aryl-Ci-C4 alkyl-, heteroaryl-Ci -C 4 alkyl-, Ci-C 4 haloalkyl, -OCi -C 4 alkyl, -OCi-C 4 alkylphenyl, -Ci-C 4 alkyl-OH, -OCi-C 4 haloalkyl, halo, -OH, -NH 2 , -C 1 -C 4 alkyl-NH 2 , -N(C 1 -C 4 alkyl)(C r C 4 alkyl), -NH(C 1 -C 4 alkyl),
  • a substituted alkoxy group is "polyalkoxy" or -O-(optionally substituted alkylene)-(optionally substituted alkoxy), and includes groups such as -OCH 2 CH 2 OCH 3 , and residues of glycol ethers such as polyethyleneglycol, and -0(CH 2 CH 2 O) x CH 3 , where x is an integer of 2-20, such as 2-10, and for example, 2-5.
  • Another substituted alkoxy group is hydroxy alkoxy or -OCH 2 (CH 2 ) y OH, where y is an integer of 1-10, such as 1-4.
  • substituted alkoxycarbonyl refers to the group (substituted alkyl)- ⁇ -
  • R b is chosen from H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R c is independently chosen from hydrogen and optionally substituted C 1 -C 4 alkyl; or
  • R b andR c and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from Ci-C 4 alkyl, aryl, heteroaryl, aryl-Ci-C4 alkyl-, heteroaryl-Ci-C 4 alkyl-, C1-C 4 haloalkyl, -OC1-C4 alkyl, -OCi-C 4 alkylphenyl, -Ci-C 4 alkyl-OH, -OCi-C 4 haloalkyl, halo, -OH, -NH 2 , -C 1 -C 4 alkyl-NH 2 , -N(C 1 -C 4 alkyl)(d-C 4 alkyl), -NH(Ci-C 4 alkyl),
  • -C(O)Ci-C 4 alkyl -C(O)Ci-C 4 alkylphenyl, -C(O)C 1 -C 4 haloalkyl, -OC(O)Ci-C 4 alkyl, - SO 2 (Ci-C 4 alkyl), -SO 2 ( ⁇ henyl), -SO 2 (Ci-C 4 haloalkyl), -SO 2 NH 2 , -SO 2 NH(Ci-C 4 alkyl), -SO 2 NH(phenyl), -NHSO 2 (Ci-C 4 alkyl), -NHSO 2 ( ⁇ henyl), and -NHSO 2 (Ci-C 4 haloalkyl).
  • substituted amino refers to the group -NHR d or -NR d R e wherein R d is chosen from: hydroxy, optionally substitued alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted acyl, optionally substituted carbamimidoyl, aminocarbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxycarbonyl, sulfinyl and sulfonyl, and wherein R e is chosen from: optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl, and wherein substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl,
  • -R a s -OR b optionally substituted amino (including -NR c COR b , -NR c CO 2 R a , -NR 0 CONRV, -NR l fc(NR c )NR b R c , -NR 15 C(NCN)NRV, and -NR c SO 2 R a ), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR b ), optionally substituted alkoxycarbonyl (such as -CO 2 R 15 ), aminocarbonyl (such as -CONR 15 R 0 ), -OCOR b , -OCO 2 R a , -OCONR 5 R 0 , sulfanyl (such as SR b ), sulfinyl (such as -
  • R b is chosen from H, optionally substituted Ci-C 6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • R c is independently chosen from hydrogen and optionally substituted Ci-C 4 alkyl; or
  • substituted amino also refers to N-oxides of the groups -NHR d .
  • N-oxides can be prepared by treatment of the corresponding amino group with, for example, hydrogen peroxide or m-chloroperoxybenzoic acid.
  • the person skilled in the art is familiar with reaction conditions for carrying out the N-oxidation.
  • Compounds of Formula I include, but are not limited to, optical isomers of compounds of Formula I, racemates, and other mixtures thereof. In those situations, the single enantiomers or diastereomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates.
  • Racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column.
  • compounds of Formula I include Z- and E- forms (or cis- and trans- forms) of compounds with carbon-carbon double bonds. Where compounds of Formula I exists in various tautomeric forms, chemical entities of the present invention include all tautomeric forms of the compound.
  • Chemical entities of the present invention include, but are not limited to compounds of Formula I and all pharmaceutically acceptable forms thereof.
  • Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, solvates, crystal forms (including polymorphs and clathrates), chelates, non-covalent complexes, prodrugs, and mixtures thereof.
  • the compounds described herein are in the form of pharmaceutically acceptable salts.
  • the terms "chemical entity” and “chemical entities” also encompass pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures.
  • “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2- hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate such as acetate, HOOC- (CHa) n -COOH where n is 0-4, and like salts.
  • inorganic acids such as hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, and like salts
  • an organic acid such as malate, maleate, fumarate, tartrate,
  • pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt, particularly a pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts.
  • prodrugs also fall within the scope of chemical entities, for example ester or amide derivatives of the compounds of Formula I.
  • the term "prodrugs” includes any compounds that become compounds of Formula I when administered to a patient, e.g., upon metabolic processing of the prodrug.
  • Examples of prodrugs include, but are not limited to, acetate, formate, phosphate, and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I.
  • solvate refers to the chemical entity formed by the interaction of a solvent and a compound. Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates.
  • chelate refers to the chemical entity formed by the coordination of a compound to a metal ion at two (or more) points.
  • non-covalent complex refers to the chemical entity formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule.
  • complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
  • active agent is used to indicate a chemical entity which has biological activity.
  • an “active agent” is a compound having pharmaceutical utility.
  • an active agent may be an anti-cancer therapeutic.
  • antimitotic refers to a drug for inhibiting or preventing mitosis, for example, by causing metaphase arrest. Some antitumour drugs block proliferation and are considered antimitotics.
  • a therapeutically effective amount of a chemical entity of this invention means an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease e.g., a therapeutically effective amount may be an amount sufficient to decrease the symptoms of a disease. In some embodiments, a therapeutically effective amount is an amount sufficient to reduce cancer symptoms. In some embodiments a therapeutically effective amount is an amount sufficient to decrease the number of detectable cancerous cells in an organism, detectably slow, or stop the growth of a cancerous tumor. In some embodiments, a therapeutically effective amount is an amount sufficient to shrink a cancerous tumor.
  • inhibitors indicates a significant decrease in the baseline activity of a biological activity or process.
  • Treatment means any treatment of a disease in a patient, including: a) preventing the disease, that is, causing the clinical symptoms of the disease not to develop; b) inhibiting the disease; c) slowing or arresting the development of clinical symptoms; and/or d) relieving the disease, that is, causing the regression of clinical symptoms.
  • Patient refers to an animal, such as a mammal, that has been or will be the object of treatment, observation or experiment. The methods of the invention can be useful in both human therapy and veterinary applications.
  • the patient is a mammal; in some embodiments the patient is human; and in some embodiments the patient is chosen from cats and dogs.
  • the present invention is directed to certain chemical entities that cause mitotic arrest and cell death. Accordingly, provided is at least one chemical entity chosen from compounds of Formula I:
  • Ri is chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl and optionally substituted heteroaryl;
  • R 2 is chosen from optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, hydroxy, and optionally substituted amino;
  • R 3 is chosen from hydrogen and optionally substituted alkyl
  • R 4 is chosen from hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted heteroaryl, aminocarbonyl, sulfonyl, optionally substituted alkoxycarbonyl, and optionally substituted cycloalkyl;
  • R 5 is chosen from hydrogen and optionally substituted alkyl
  • R 6 is chosen from optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, hydroxy, and optionally substituted amino provided that: the compound of Formula I is not dimethyl l-benzylpiperidine-3,5-dicarboxylate; methyl 5-acetyl-l-benzylpiperidine-3-carboxylate; dimethyl l-benzyl-4-phenylpiperidine-3,5- dicarboxylate; (l-methyl-4-phenylpiperidine-3,5-diyl)bis(phenylmethanone); (1-benzyl- 4-phenylpiperidine-3,5-diyl)bis(phenylmethanone); ( 1 -(2-hydroxyethyl)-4- phenylpiperidine-3 ,5-diyl)b is (phenylmethanone); ( 1 -
  • Rj is chosen from hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • Ri is chosen from optionally substituted aryl and optionally substituted heteroaryl.
  • Ri is chosen from aryl and heteroaryl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, hydroxy, cyano, optionally substituted acyl, optionally substituted alkoxycarbonyl, carboxyl, optionally substituted aminocarbonyl, and sulfonyl.
  • Ri is chosen from aryl and heteroaryl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, cyano, optionally substituted lower alkoxy, and hydroxy',
  • Ri is chosen from aryl and heteroaryl, either of which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, hydroxy, carboxyl, methoxycarbonyl, aminocarbonyl, N- methylaminocarbonyl, N,N-dimethylaminocarbonyl, cyano, hydroxymethyl, aminomethyl, acetamidomethyl, methylsulfonyl, acetyl, and isopropyl.
  • Ri is chosen from aryl and heteroaryl, either of which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, cyano, and hydroxy. [0065] hi some embodiments, Ri is chosen from optionally substituted phenyl and optionally substituted pyridinyl.
  • Ri is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, hydroxy, cyano, optionally substituted acyl, optionally substituted alkoxycarbonyl, carboxyl, optionally substituted aminocarbonyl, and sulfonyl.
  • Ri is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, cyano, optionally substituted lower alkoxy, and hydroxy.
  • Ri is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, hydroxy, carboxyl, methoxycarbonyl, aminocarbonyl, N- methylaminocarbonyl, N,N-dimethylaminocarbonyl, cyano, hydroxymethyl, aminomethyl, acetamidomethyl, methylsulfonyl, acetyl, and isopropyl.
  • Ri is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen from halo, methyl, txifluoromethyl, ethyl, methoxy, ethoxy, cyano, and hydroxy. [0067] hi some embodiments, Ri is chosen from hydrogen, phenyl, 2,3-dimethylphenyl,
  • Ri is chosen from phenyl, 2,3- dimethylphenyl, 3-halo-2-methylphenyl, 2,3-dihalophenyl, 2-methylphenyl, and pyridinyl.
  • R 2 is chosen from optionally substituted amino, optionally substituted aryl and optionally substituted heteroaryl.
  • R 2 is chosen from -NRgRg wherein Rs and Rg together with the nitrogen to which they are bound form a 4- to 8-membered heterocycloalkyl ring which optionally includes an additional heteroatom chosen from O, S, and N, which 4- to 8-membered heterocycloalkyl ring optionally is fused to an aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring and wherein the 4- to 8-membered heterocycloalkyl ring is optionally substituted with one, two, or three groups chosen from optionally substituted phenyl, aminocarbonyl, alkoxycarbonyl, halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.
  • R 2 is chosen from -NRsRg wherein R 8 and Rg together with the nitrogen to which they are bound form a 4- to 8-membered heterocycloalkyl ring which optionally includes an additional heteroatom chosen from O, S, and N, aryl, and heteroaryl, each of which is optionally substituted with one, two, or three groups chosen from aminocarbonyl, alkoxycarbonyl, lower alkoy, lower alkoxy, halo, trifluoromethyl, and hydroxy.
  • R 2 is piperidinyl-1-yl or pyrrolidin-1-yl, each of which is optionally substituted with one or two groups chosen from aminocarbonyl, lower alkoxycarbonyl, methoxymethyl, halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R2 is pyrrolidin-1-yl, optionally substituted with one or two groups chosen from aminocarbonyl, lower alkoxycarbonyl, methoxymethyl, halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R 2 is pyrrolidin-1- yl, optionally substituted with trifluoromethyl or methyl.
  • R 2 is (S)-2- (trifluoromethyl)pyrrolidin-l-yl or (R)-2-(trifluoromethyl)pyrrolidin-l-yl .
  • R 2 is chosen from -NR10R11 wherein Ri 0 is chosen from hydrogen and optionally substituted alkyl, and Ru is chosen from alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
  • Rio is chosen from hydrogen and optionally substituted lower alkyl. In some embodiments, Rio is chosen from hydrogen and methyl. In some embodiments, Rn is chosen from optionally substituted phenyl, optionally substituted lower alkyl, and optionally substituted cycloalkyl. In some embodiments, Ri i is chosen from phenyl, optionally substituted lower alkyl, and cycloalkyl. [0072] In some embodiments, R 2 is chosen from optionally substituted aryl and optionally substituted heteroaryl.
  • R 2 is chosen from aryl and heteroaryl, each of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy. In some embodiments, R 2 is chosen from aryl and heteroaryl, either of which is which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R 2 is chosen from optionally substituted phenyl and optionally substituted pyridinyl.
  • R 2 is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.
  • R2 is chosen from phenyl and pyridinyl, either of which is which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R 2 is chosen from phenyl, hydroxyphenyl, and pyridinyl.
  • R 2 is optionally substituted alkoxy. In some embodiments,
  • R2 is optionally substituted lower alkoxy. In some embodiments, R 2 is ethoxy.
  • R 3 is chosen from hydrogen and optionally substituted lower alkyl. In some embodiments, R 3 is chosen from hydrogen and lower alkyl. In some embodiments, R 3 is chosen from hydrogen and methyl. In some embodiments, R 3 is hydrogen.
  • R 4 is chosen from hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted heteroaryl, aminocarbonyl, sulfonyl, optionally substituted alkoxycarbonyl, and optionally substituted cycloalkyl.
  • R 4 is chosen from hydrogen, optionally substituted acyl, optionally substituted aminocarbonyl, optionally substituted sulfonyl, optionally substituted alkoxycarbonyl optionally substituted lower alkyl, and optionally substituted cycloalkyl.
  • R 4 is chosen from hydrogen, allyl, acyl substituted with optionally substituted lower alkyl, aminocarbonyl substituted with optionally substituted lower alkyl, sulfonyl substituted with optionally substituted lower alkyl, alkoxycarbonyl substituted with optionally substituted lower alkyl, and lower alkyl optionally substituted with optionally substituted phenyl, hydroxy, lower alkoxy, alkoxycarbonyl, optionally substituted aminocarbonyl, heterocycloalkyl, acyloxy, optionally substituted amino, and carboxy.
  • R 4 is chosen from hydrogen, 2-hydroxyethyl, benzyl, 2- methoxyethyl, 2-hydroxycyclopentyl, l,3-dihydroxypropan-2-yl, cyclopentyl, methyl, 2- morpholinoethyl, 2-methoxy-2-oxoethyl, 2-(methylamino)-2-oxoethyl, 2-acetoxyethyl, (R)-I- hydroxypropan-2-yl, (S)-l-hydroxypropan-2-yl, (R)-2-hydroxypropyl, (S)-2-hydroxypropyl, propyl, 2-(dimethylamino)ediyl, 2-(piperazin-l-yl)ethyl, 2-amino-2-oxoethyl, carboxymethyl, 3- hydroxypropyl, ethyl, 3-ethoxy-3-oxopropyl, l,3-dihydroxypropan-2
  • R 5 is chosen from hydrogen and optionally substituted lower alkyl. In some embodiments, R5 is chosen from hydrogen and lower alkyl. In some embodiments, R 5 is chosen from hydrogen and methyl. In some embodiments, R 5 is hydrogen. [0078] In some embodiments, R$ is chosen from optionally substituted amino, optionally substituted aryl and optionally substituted heteroaryl.
  • Re is chosen from -NR 8 Rg wherein Rg and Rp together with the nitrogen to which they are bound form a 4- to 8-membered heterocycloalkyl ring which optionally includes an additional heteroator ⁇ chosen from O, S, and N, which 4- to 8-membered heterocycloalkyl ring optionally is fused to an aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring and wherein the 4- to 8-membered heterocycloalkyl ring is optionally substituted with one, two, or three groups chosen from optionally substituted phenyl, aminocarbonyl, alkoxycarbonyl, halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.
  • R 6 is chosen from -NR 8 R 9 wherein Rg and Rg together with the nitrogen to which they are bound form a 4- to 8-membered heterocycloalkyl ring which optionally includes an additional heteroatom chosen from O, S, and N, aryl, and heteroaryl, each of which is optionally substituted with one, two, or three groups chosen from aminocarbonyl, alkoxycarbonyl, lower alkoy, lower alkoxy, halo, trifluoromethyl, and hydroxy.
  • R 6 is piperidinyl-1-yl or pyrrolidin-1-yl, each of which is optionally substituted with one or two groups chosen from aminocarbonyl, lower alkoxycarbonyl, methoxymethyl, halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R 6 is pyrrolidin-1-yl, optionally substituted with one or two groups chosen from aminocarbonyl, lower alkoxycarbonyl, methoxymethyl, halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • Re is pyrrolidin-1- yl, optionally substituted with trifluoromethyl or methyl.
  • Rg is (S)-2- (trifluoromethyl)pyrrolidin-l-yl or (R)-2-(trifluoromethyl)pyrrolidin-l-yl .
  • R 6 is chosen from -NRioR ⁇ wherein Rio is chosen from hydrogen and optionally substituted alkyl, and Rn is chosen from alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
  • Ri 0 is chosen from hydrogen and optionally substituted lower alkyl. In some embodiments, Rio is chosen from hydrogen and methyl. In some embodiments, Ri i is chosen from optionally substituted phenyl, optionally substituted lower alkyl, and optionally substituted cycloalkyl. In some embodiments, Ri i is chosen from phenyl, optionally substituted lower alkyl, and cycloalkyl. [0082] In some embodiments, Re is chosen from optionally substituted aryl and optionally substituted heteroaryl.
  • R 6 is chosen from aryl and heteroaryl, each of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.
  • Re is chosen from aryl and heteroaryl, either of which is which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R$ is chosen from optionally substituted phenyl and optionally substituted pyridinyl.
  • Re is chosen from phenyl and pyridinyl, either of which is optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.
  • Re is chosen from phenyl and pyridinyl, either of which is which is optionally substituted with one, two, or three groups chosen from halo, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, and hydroxy.
  • R 6 is chosen from phenyl, hydroxyphenyl, and pyridinyl.
  • R 2 is the same as R 6 . In some embodiments, they are different. In some embodiments, if R 2 is optionally substituted alkoxy, hydroxy, or optionally substituted amino; then Re is optionally substituted aryl or optionally substituted heteroaryl.
  • R 7 is chosen from hydrogen and optionally substituted lower alkyl. In some embodiments, R 7 is chosen from hydrogen and lower alkyl. In some embodiments, R 7 is hydrogen.
  • the compounds of Formula I have cis, cw-stereochemistry.
  • the compounds of Formula I have cis, /rans-stereochemistry. In some embodiments, the compounds of Formula I have trans, frans-stereochemistry.
  • the compounds of the invention can be synthesized utilizing techniques well known in the art from commercially available starting materials and reagents.
  • the compounds of the invention can be prepared as shown below:
  • Step 1 to a stirred solution of an excess, such as about 2.4 equivalents, of a compound of Formula 101 and a compound of Formula 102 in an inert solvent such as dichloromethane is added a base such as aqueous sodium hydroxide (for example, 50% aqueous sodium hydroxide) and tetrabutylammonium bromide.
  • a base such as aqueous sodium hydroxide (for example, 50% aqueous sodium hydroxide) and tetrabutylammonium bromide.
  • the resulting solution is stirred vigorously at room temperature for about 3 hour.
  • the product, a compound of Formula 103 is isolated and optionally purified.
  • Step 3 a compound of Formula 104 and a base such as DlEA in an inert solvent such as acetonitrile is treated with about an equivalent of iodomethane.
  • the mixture is stirred at room temperature for about 2 h.
  • Base such as aqueous potassium hydroxide, for example, 1 M potassium hydroxide, is added and the reaction heated to about 70 0 C for about 30 min.
  • the product, a compound of Formula 105 is isolated and optionally purified.
  • a mixture of cis/trans and trans/trans isomers is obtained, that mixture can be converted to the trans/trans product by treatment with a polar, protic solvent such as methanol and aqueous base, such as aqueous relieassium hydroxide, for example, 1 M potassium hydroxide, at about 75 0 C for about 2 h.
  • a polar, protic solvent such as methanol
  • aqueous base such as aqueous relieassium hydroxide, for example, 1 M potassium hydroxide
  • Formula 201 in an inert solvent such as acetonitrile is added an excess (such as about 4.9 equivalents) of a compound of formula NH 2 R 4 .
  • the solution is stirred for about 1 h and then treated with base, such as aqueous potassium hydroxide (e.g., 1 M aqueous potassium hydroxide).
  • base such as aqueous potassium hydroxide (e.g., 1 M aqueous potassium hydroxide).
  • the mixture may be stirred at reflux for 1.5 h to achieve complete epimerization to a single diastereomeric (trans, trans) form by LCMS.
  • the product, a compound of Formula 106 is isolated and optionally purified.
  • Step 1 to a stirred solution of an excess such as greater than two equivalents (e.g., 2.4 equivalents) of a compound of Formula 101 and a compound of Formula 102 in an inert solvent such as dichloromethane is added base such as aqueous sodium hydroxide (e.g., 10% aqueous sodium hydroxide) and tetrabutylammonium bromide using a water/ice bath to maintain room temperature. The resulting mixture is stirred vigorously at room temperature for about 16 h. An additional portion of tetrabutylammonium bromide may be added and the mixture stirred an additional 3 h.
  • the product, a compound of Formula 103 is isolated and optionally purified.
  • Step 2 a mixture of a compound of Formula 103 and an excess such as about 4.6 equivalents of Eschenmoser's salt in a polar protic solvent such as acetic acid is stirred at about 120 C under nitrogen for about 16 h. An additional amount of Eschenmoser's salt may be added and the mixture may be heated an additional 2 h.
  • the product, a compound of Formula 104, is isolated and optionally purified.
  • Formula 104 in an inert solvent such as acetonitrile is added a base such as diisopropylethylamine followed by an excess (such as more than 10 equivalents, e.g., 12 equivalents) of iodomethane.
  • a base such as diisopropylethylamine followed by an excess (such as more than 10 equivalents, e.g., 12 equivalents) of iodomethane.
  • base such as aqueous potassium hydroxide (e.g., 2 M aqueous potassium hydroxide) and the temperature is raised to about 75 ° C for about 16 h.
  • the product, a compound of Formula 105 is isolated and optionally purified.
  • Formula 105 in an inert solvent such as DMF is heated to about 80 C.
  • An excess (e.g., 7 equivalents) of a compound of formula NH 2 R 4 is added slowly over 10 min.
  • the heated solution is stirred for about 45 min.
  • the product, a compound of Formula 106, is isolated and optionally purified.
  • Formula 101 in an inert solvent such as IMS is added a compound of Formula 102.
  • Base such as aqueous sodium hydroxide (e.g., 10% aqueous sodium hydroxide) is added over about 40 min using a water bath to maintain a temperature between 18-25 C.
  • aqueous sodium hydroxide e.g., 10% aqueous sodium hydroxide
  • the product, a compound of Formula 401, is isolated and optionally purified.
  • Step 1 a mixture of a compound of Formula
  • Formula 105 in an inert solvent such as acetonitrile is added an excess (such as about 4 equivalents) of benzylamine.
  • the solution is stirred for about 3 h.
  • aqueous base such as 1 M aqueous potassium hydroxide
  • the solution is refluxed for about 16 h to achieve epimerization to mainly the (trans,trans) diastereoisomeric form by LCMS.
  • the product, a compound of Formula 701 is isolated and optionally purified.
  • Reaction Scheme 7 to a compound of Formula 701 is added an excess of methyl chloroformate. The reaction mixture is stirred at room temperature for about 2 h. The product, a compound of Formula 703, is isolated and optionally purified.
  • a compound of Formula 703 is treated with concentrated HBr (such as 48% HBr) and the mixture is stirred at room temperature for about 16 h. The product, a compound of Formula 705, is isolated and optionally purified.
  • Reaction Scheme 8 to a compound of Formula 701 is added an excess of methyl chloroformate. The reaction mixture is stirred at room temperature for about 2 h. The product, a compound of Formula 703, is isolated and optionally purified.
  • concentrated HBr such as 48% HBr
  • Formula 1001 in a polar protic solvent such as methanol is added aqueous base (such as aqueous potassium hydroxide, e.g., IM potassium hydroxide).
  • aqueous base such as aqueous potassium hydroxide, e.g., IM potassium hydroxide.
  • the resulting solution is stirred at about 60 0 C for about 16 h.
  • the product, a compound of Formula 1003, is isolated and optionally purified.
  • the chemical entities described herein are administered as a pharmaceutical composition or formulation.
  • pharmaceutical formulations comprising at least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients.
  • Pharmaceutically acceptable vehicles must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated.
  • the vehicle can be inert or it can possess pharmaceutical benefits.
  • the amount of vehicle employed in conjunction with the chemical entity is sufficient to provide a practical quantity of material for administration per unit dose of the chemical entity.
  • Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; iso
  • Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the chemical entity of the present invention.
  • Effective concentrations of at least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are mixed with a suitable pharmaceutical acceptable vehicle.
  • methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate.
  • cosolvents such as dimethylsulfoxide (DMSO)
  • surfactants such as TWEEN
  • the resulting mixture may be a solution, suspension, emulsion or the like.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the chemical entity in the chosen vehicle.
  • the effective concentration sufficient for ameliorating the symptoms of the disease treated may be empirically determined.
  • Chemical entities described herein may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
  • Dosage formulations suitable for oral use include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations.
  • oral formulations contain from 0.1 to 99% of at least one chemical entity described herein.
  • oral formulations contain at least 5% (weight %) of at least one chemical entity described herein. Some embodiments contain from 25% to 50% or from 5% to 75 % of at least one chemical entity described herein.
  • Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like.
  • the pharmaceutically acceptable carriers suitable for preparation of such compositions are well known in the art.
  • Oral formulations may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masking agents, and coloring agents.
  • Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent. [00122] Chemical entities described herein can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example.
  • formulations containing these chemical entities can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoate and sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose
  • typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
  • Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • compositions of the invention may also be in the form of oil-in- water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
  • Dispers ⁇ ble powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol
  • Tablets typically comprise conventional pharmaceutically acceptable adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, can be useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.
  • compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the chemical entity is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action.
  • dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable vehicle, for example as a solution in 1,3-butanediol.
  • a non-toxic parentally acceptable vehicle for example as a solution in 1,3-butanediol.
  • acceptable vehicles that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can be useful in the preparation of injectables.
  • Chemical entities described herein may be administered parenterally in a sterile medium.
  • Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques. Chemical entities described herein, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
  • the carrier comprises at least 90% by weight of the total composition.
  • the carrier for parenteral administration is chosen from propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil.
  • Chemical entites described herein may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter and polyethylene glycols.
  • Chemical entities described herein may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye.
  • Topical compositions may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
  • Such solutions may be formulated as 0.01% -10% isotonic solutions, pH 5-7, with appropriate salts.
  • Chemical entities described herein may also be formulated for transdermal administration as a transdermal patch.
  • Topical compositions comprising at least one chemical entity described herein can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
  • carrier materials such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
  • Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders.
  • Representative emollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane- 1,2-diol, butane- 1,3-diol, mink oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, iso-propyl stearate, butyl stearate, polyethylene glyco
  • Chemical entities described herein may also be topically administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • compositions useful for attaining systemic delivery of the chemical entity include sublingual, buccal and nasal dosage forms.
  • Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
  • compositions for inhalation typically can be provided in the form of a solution, suspension or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).
  • a conventional propellant e.g., dichlorodifluoromethane or trichlorofluoromethane.
  • the compositions of the present invention may also optionally comprise an activity enhancer.
  • the activity enhancer can be chosen from a wide variety of molecules that function in different ways to enhance or be independent of therapeutic effects of the chemical entities described herein. Particular classes of activity enhancers include skin penetration enhancers and absorption enhancers.
  • compositions of the invention may also contain additional active agents that can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of at least one chemical entity described herein. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from 0.01% to 15%. Some embodiments contain from 0.1% to 10% by weight of the composition. Other embodiments contain from 0.5% to 5% by weight of the composition. [00144] The invention includes packaged pharmaceutical formulations.
  • Such packaged formulations include a pharmaceutical composition comprising at least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, and instructions for using the composition to treat a mammal (typically a human patient).
  • the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition of Btk activity and/ or inhibition of B-cell activity.
  • the invention can include providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
  • chemical entities can be administered alone, as mixtures, or in combination with other active agents.
  • the chemical entities described herein can be used to treat cellular proliferation diseases.
  • diseases include, but are not limited to, cancer (further discussed below), autoimmune disease, fungal disorders, arthritis, graft rejection, inflammatory bowel disease, cellular proliferation induced after medical procedures, including, but not limited to, surgery, angioplasty, and the like.
  • Treatment includes inhibiting cellular proliferation. It is appreciated that in some cases the cells may not be in an abnormal state and still require treatment.
  • at least one chemical entity is administered to cells or individuals afflicted or subject to impending affliction with any one of these diseases or states.
  • the chemical entities provided herein can be used to treat cancer including solid tumors such as skin, breast, brain, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that can be treated include, but are not limited to:
  • sarcoma angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma
  • myxoma rhabdomyoma, fibroma, lipoma and teratoma
  • Lung bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
  • Gastrointestinal esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);
  • kidney adenocarcinoma, WiIm' s tumor [nephroblastoma], lymphoma, leukemia
  • bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
  • Liver hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
  • Bone osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxof ⁇ broma, osteoid osteoma and giant cell tumors; • Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma
  • Gynecological uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli- Leydig cell tumors, dysgerminoma, malignant tertoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma);
  • Hematologic blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma];
  • Skin malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and
  • Adrenal glands neuroblastoma.
  • treatment of cancer includes treatment of cancerous cells.
  • the chemical entities provided herein may be demonstrated to inhibit tumor cell proliferation, cell transformation and tumorigenesis in vitro and in vivo using a variety of assays known in the art, or described herein. Such assays may use cells of a cancer cell line, or cells from a patient.
  • cell proliferation can be assayed by measuring 3 H-thymidine incorporation, by direct cell count, by detecting changes in transcription, translation or activity of known genes such as proto-oncogenes (e.g., fos, myc) or cell cycle markers (Rb, cdc2, cyclin A, Dl, D2, D3, E, etc).
  • proto-oncogenes e.g., fos, myc
  • cell cycle markers Rb, cdc2, cyclin A, Dl, D2, D3, E, etc.
  • the levels of such protein and mRNA and activity can be determined by any method well known in the art.
  • Cell proliferation may be measured by counting samples of a cell population over time (e.g., daily cell counts). Cells may be counted using a hemacytometer and light microscopy (e.g., HyLite hemacytometer, Hausser Scientific). Cell number may be plotted against time in order to obtain a growth curve for the population of interest. In one embodiment, cells are first mixed with the dye Trypan-blue (Sigma), such that living cells exclude the dye, and are counted as viable members of the population.
  • Trypan-blue Sigma
  • DNA content and/or mitotic index of the cells may be measured, for example, based on DNA ploidy value of the cell.
  • cells in the Gl phase of the cell cycle generally contain a 2N DNA ploidy value.
  • Cells in which DNA has been replicated but have not progressed through mitosis e.g., cells in S-phase
  • Ploidy value and cell-cycle kinetics may be further measured using propidum iodide assay (see, e.g., Turner, T., et al., 1998, Prostate 34:175-81).
  • the DNA ploidy maybe determined by quantitation of DNA Feulgen staining (which binds to DNA in a stoichiometric manner) on a computerized microdensitometrystaining system (see, e.g., Bacus, S., 1989, Am. J. Pathol. 135:783-92).
  • DNA content may be analyzed by preparation of a chromosomal spread (Zabalou, S., 1994, Hereditas. 120: 127-40; Pardue, M.L., 1994, Meth. Cell Biol. 44:333-351).
  • Detection of changes in length of the cell cycle or speed of cell cycle may also be used to measure inhibition of cell proliferation by the compounds of the invention.
  • the length of the cell cycle is determined by the doubling time of a population of cells (e.g., using cells contacted or not contacted with one or more compounds of the invention).
  • FACS analysis is used to analyze the phase of cell cycle progression, or purify Gl, S, and G2/M fractions (see e.g., Delia, D. et al., 1997, Oncogene 14:2137-47).
  • Lapse of cell cycle checkpoint(s), and/or induction of cell cycle checkpoint(s) may be examined by any method known in the art.
  • a cell cycle checkpoint is a mechanism which ensures that certain cellular events occur in a particular order.
  • Checkpoint genes are defined by mutations that allow late events to occur without prior completion of an early event (Weinert, T., and Hartwell, L., 1993, Genetics 134:63-80). Induction or inhibition of cell cycle checkpoint genes may be assayed, for example, by Western blot analysis, or by immunostaining, etc. Lapse of cell cycle checkpoints may be further assessed by the progression of a cell through the checkpoint without prior occurrence of specific events (e.g., progression into mitosis without complete replication of the genomic DNA).
  • cell culture models include, but are not limited to, for lung cancer, primary rat lung tumor cells (Swafford et al., 1997, MoI. Cell. Biol. 17:1366-1374) and large-cell undifferentiated cancer cell lines (Mabry et al., 1991, Cancer Cells 3:53-58); colorectal cell lines for colon cancer (Park and Gazdar,1996, J. Cell Biochem. Suppl. 24:131-141); multiple established cell lines for breast cancer (Hambly et al., 1997, Breast Cancer Res. Treat.
  • the chemical entities provided herein can also be demonstrated to inhibit cell growth (or mitosis) in vitro. Li this embodiment, cells are contacted with one or more chemical entities provided herein, and examined for lethal phenotype.
  • chemical entities provided herein can be administered to a test animal, preferably a test animal predisposed to develop a type of tumor, and the test animal subsequently examined for a decreased incidence of tumor formation in comparison with controls not administered the compound.
  • chemical entities provided herein can be administered to test animals having tumors (e.g., animals in which tumors have been induced by introduction of malignant, neoplastic, or transformed cells, or by administration of a carcinogen) and subsequently examining the tumors in the test animals for tumor regression in comparison to controls not administered the chemical entity.
  • GI 50 defined as the concentration of the chemical entity that results in a decrease in the rate of cell growth by fifty percent.
  • the chemical entity has a GI 50 of less than about 1 mM; alternatively, the chemical entity has a GI 50 of less than about 20 ⁇ M, less than about 10 ⁇ M, less than about 1 ⁇ M, less than about 100 nM, or less than about 10 nM.
  • Measurement of GI 50 is done using a cell proliferation assay such as described herein. Chemical entities provided herein were found to inhibit cell proliferation.
  • In vitro potency of chemical entities provided herein can be determined, for example, by assaying human ovarian cancer cells (SKO V3) for viability following a 72-hour exposure to a 9-point dilution series of compound. Cell viability is determined by measuring the absorbance of formazon, a product formed by the bioreduction of MTS/PMS, a commercially available reagent. Each point on the dose-response curve is calculated as a percent of untreated control cells at 72 hours minus background absorption (complete growth inhibition).
  • Anti-proliferative compounds that have been successfully applied in the clinic to treatment of cancer have GIso's that vary greatly.
  • Chemical entities provided herein may be administered, for example, as a pharmaceutically acceptable composition, to a patient. Depending upon the manner of introduction, the chemical entities may be formulated in a variety of ways as discussed below.
  • the concentration of therapeutically active chemical entity in the formation may vary from about 0.1-10 wt.%.
  • the chemical entity may be administered alone or in combination with other treatments, i.e., radiation, or other chemotherapeutic agents such as the taxane class of agents that appear to act on microtubule formation or the camptothecin class of topoisomerase I inhibitors.
  • other chemotherapeutic agents may be administered before, concurrently, or after administration of at least one chemical entity provided herein.
  • at least one chemical entity provided herein is co-administered with one or more other chemotherapeutic agents.
  • co-administer it is meant that at least one chemical entity provided herein is administered to a patient such that the chemical entity as well as the coadministered compound may be found in the patient's bloodstream at the same time, regardless of when the compounds are actually administered, including simultaneously.
  • the resulting residue was partitioned between ethyl acetate and sodium bicarbonate, and the organic layer was dried over sodium sulfate, filtered and evaporated to dryness.
  • the foamy white solid was then dissolved in a mixture of methanol (100 mL) and 1 M KOH (50 mL) and stirred at 75 0 C for 2 h, at which point LC/MS showed complete conversion to the trans/trans product.
  • the solution was cooled to room temperature and extracted with ethyl acetate (2 x 150 mL). The combined organic layers were dried over sodium sulfate and evaporated to dryness.
  • Nl,Nl,N2-trimethylethane- 1,2-diamine (0.072 mL, 0.63 mmol) was added and the mixture stirred a further 30 min.
  • the reaction was diluted with saturated NaCl (40 mL) and extracted with EtOAc (3 x 40 mL).
  • This reaction was then combined with a pilot scale reaction at the same stage (starting from 59 g of 3 using the same condition outlined above).
  • the combined reaction mixtures were concentrated and diluted with ethyl acetate (1 L) and a saturated solution of potassium carbonate (300 mL).
  • the organic layer was separated, dried over Na 2 SO 4 , filtered, and concentrated.
  • the reaction was stirred for 1 h at 0 0 C.
  • the reaction was quenched by the addition of ammonium chloride, followed by the addition of ethyl acetate (300 mL).
  • the organic layer was separated and dried over Na 2 SC> 4 , filtered, and concentrated.
  • In vitro potency of small molecule inhibitors is determined by assaying human ovarian cancer cells (SKO V3) for viability following a 72-hour exposure to a 10-point dilution series of compound. Cell viability is determined by measuring the absorbance of formazon, a product formed by the bioreduction of MTS/PMS, a commercially available reagent. Each point on the dose-response curve is calculated as a percent of untreated control cells at 72 hours minus background absorption (complete growth inhibition).
  • Control Compound for max cell kill Topotecan, IuM
  • ODs from these wells will be used to subtract out for background absorbance of dead cells and vehicle.
  • Certain of the chemical entities described herein were evaluated for in vivo activity against SKOV-3 human ovarian carcinoma in a tumor growth delay (TGD) study.
  • TTD tumor growth delay
  • a first chemical entity was evaluated at doses of 300 or 150 mg/kg administered intraperitoneally (i.p.) once daily and at 150 mg/kg administered i.p. twice daily. Doses were administered on study days 1 to 5 and 8 to 12. Tumors were measured twice weekly during the 60-day study.
  • TTE time to endpoint
  • the 250 and 500 mg/kg once daily treatments produced 15 and 58% TGD, respectively, which was statistically significant activity at 500 mg/kg.
  • the 250 mg/kg twice daily treatment produced 57% TGD, which was statistically significant activity.
  • a second chemical entity was similarly evaluated at 500 mg/kg administered i.p. once daily. That chemical entity produced 35% TGD, which was statistically significant activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés utiles pour traiter des maladies prolifératives cellulaires.
PCT/US2006/044753 2005-11-15 2006-11-15 Entites chimiques, compositions et methodes WO2007059323A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06837964A EP1962846A2 (fr) 2005-11-15 2006-11-15 Entites chimiques, compositions et methodes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73722605P 2005-11-15 2005-11-15
US60/737,226 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007059323A2 true WO2007059323A2 (fr) 2007-05-24
WO2007059323A3 WO2007059323A3 (fr) 2007-12-27

Family

ID=38049321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044753 WO2007059323A2 (fr) 2005-11-15 2006-11-15 Entites chimiques, compositions et methodes

Country Status (6)

Country Link
US (1) US7572814B2 (fr)
EP (1) EP1962846A2 (fr)
AR (1) AR058839A1 (fr)
PE (1) PE20071079A1 (fr)
TW (1) TW200738236A (fr)
WO (1) WO2007059323A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000811A1 (fr) * 2007-06-25 2008-12-31 Novartis Ag Composés organiques
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
WO2016112284A1 (fr) * 2015-01-09 2016-07-14 Genentech, Inc. Dérivés de (pipéridin-3-yl)(naphtalén-2-yl)méthanone et composés associés utilisés comme inhibiteurs de l'histone déméthylase kdm2b pour le traitement du cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445758B1 (fr) * 2016-06-29 2020-11-04 The Scripps Research Institute Diprovocims: une nouvelle classe puissante d'agonistes tlr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495192A (en) * 1982-04-30 1985-01-22 Kyowa Hakko Kogyo Co., Ltd. 1-Substituted 1,4-dihydropyridines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932645A (en) * 1971-04-10 1976-01-13 Farbenfabriken Bayer Ag Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
DE3601196A1 (de) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
WO2007059113A2 (fr) * 2005-11-15 2007-05-24 Cytokinetics, Inc. Entites chimiques, compositions et methodes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495192A (en) * 1982-04-30 1985-01-22 Kyowa Hakko Kogyo Co., Ltd. 1-Substituted 1,4-dihydropyridines

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129411B2 (en) 2005-12-30 2012-03-06 Novartis Ag Organic compounds
WO2009000811A1 (fr) * 2007-06-25 2008-12-31 Novartis Ag Composés organiques
EA016446B1 (ru) * 2007-06-25 2012-05-30 Новартис Аг Производные n5-(2-этоксиэтил)-n3-(2-пиридинил)-3,5-пиперидиндикарбоксамида, предназначенные для применения в качестве ингибиторов ренина
EP2527338A1 (fr) * 2007-06-25 2012-11-28 Novartis AG Dérivés de n5-(2-éthoxyéthyl)-n3-(2-pyridinyl) -3,5-pipéridinedicarboxamide en tant qu'inhibiteurs de la rénine
US8383650B2 (en) 2007-06-25 2013-02-26 Novartis Ag Organic compounds
KR101238479B1 (ko) * 2007-06-25 2013-03-04 노파르티스 아게 레닌 억제제로 사용하기 위한 ｎ５-(２-에톡시에틸)-ｎ３-(２-피리디닐)-３,５-피페리딘디카르복스아미드 유도체
US8497286B2 (en) 2007-06-25 2013-07-30 Novartis Ag Organic compounds
TWI404714B (zh) * 2007-06-25 2013-08-11 Novartis Ag 有機化合物
WO2016112284A1 (fr) * 2015-01-09 2016-07-14 Genentech, Inc. Dérivés de (pipéridin-3-yl)(naphtalén-2-yl)méthanone et composés associés utilisés comme inhibiteurs de l'histone déméthylase kdm2b pour le traitement du cancer
CN107406414A (zh) * 2015-01-09 2017-11-28 基因泰克公司 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶‑3‑基)(萘‑2‑基)甲酮衍生物及其相关化合物
US10280149B2 (en) 2015-01-09 2019-05-07 Genentech, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
WO2007059323A3 (fr) 2007-12-27
US20070161674A1 (en) 2007-07-12
PE20071079A1 (es) 2007-12-16
EP1962846A2 (fr) 2008-09-03
US7572814B2 (en) 2009-08-11
TW200738236A (en) 2007-10-16
AR058839A1 (es) 2008-02-27

Similar Documents

Publication Publication Date Title
DE69434041T2 (de) Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
AU767179B2 (en) Pyrrolidine modulators of chemokine receptor activity
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
JP3098035B2 (ja) 認識機能を向上させる複素環式エーテル化合物
TWI344955B (en) Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
DE69723104T2 (de) Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel
AU770491B2 (en) Pyrrolidine modulators of chemokine receptor activity
JP5814917B2 (ja) 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物
IL103613A (en) VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them.
DE102006042143A1 (de) Neue substituierte Bipyridin-Derivate und ihre Verwendung
AU9206798A (en) Pyrrolidine and piperidine modulators of chemokine receptor activity
DE69722656T2 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE19955340A1 (de) CCR-3-Rezeptor-Antagonisten
WO2003062234A1 (fr) Composes de quinoxaline
KR20140124398A (ko) 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
AU2004209495A1 (en) Pyrazole derivative
JP2006511500A (ja) γ−アミノアミド系のケモカイン受容体活性調節剤
JP2004512323A (ja) Ｃｃｒ５ケモカイン受容体活性のピロリジンモジュレーター
JP2006508948A (ja) ケモカイン受容体活性のヘテロアリールピペリジンモジュレーター
KR20100052507A (ko) ｍＧｌｕ５ 길항제로서의 신규 헤테로 고리 화합물
HU221811B1 (hu) N-acilezett-piperidin-származékok, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
AU616708B2 (en) 4-heteropentacyclic-4-{n-(phenyl)amido}piperidine derivatives and pharmaceutical compositions and method employing such compounds
WO2007059323A2 (fr) Entites chimiques, compositions et methodes
JP3001978B2 (ja) ブラジキニンアンタゴニストとしてのジヒドロピリジン誘導体
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006837964

Country of ref document: EP